Consequently, food companies are rushing to reformulate products for protein lovers. That’s a category that includes both people taking the powerful new class of obesity drugs known as GLP-1s, who are ...

Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

The luster is starting to wear off GLP-1 weight-loss drugs including Wegovy and Ozempic as more clinicians warn patients ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply improving this year, and brushed off fears of the company falling behind Eli Lilly & Co. Details about its next-generation weight loss drugs ...

Eli Lilly faces stiff competition in the GLP-1 market, primarily from Novo Nordisk (NYSE:NVO) with its products Ozempic and Wegovy. However, Eli Lilly has been gaining ground, with its ...

Eli Lilly faces stiff competition in the GLP-1 market, primarily from Novo Nordisk (NYSE:NVO) with its products Ozempic and Wegovy. However, Eli Lilly has been gaining ground, with its prescription ...

Novo believes CagriSema could be more powerful than its blockbuster weight-loss injection Wegovy, but investors are worried whether it will be good enough to retake the lead from rival Eli Lilly ...